QuarterWatch™ Reports

An independent perspective on emerging drug risks

QuarterWatch™ is published four times a year as a public service to provide an independent perspective on emerging drug risks. This scientific publication uses as its primary source recently released reports submitted to the US Food and Drug Administration (FDA) Adverse Event Reporting System (FAERS).

Browse Issues

How Well Do Antidepressant Drugs Work? Vortioxetine (TRINTELLIX) Case Study • Dispensing Errors, Name Confusion for Breo, Anoro, and other Ellipta Inhalers• Abuse of a Widely Used OTC Drug for Diarrhea
Limited system for removing/replacing expiring implants and IUDs • Emergency contraception reports mostly about abnormal menses • Psychiatric symptoms linked to hormonal contraceptives • Missed dose, thrombotic events top issues for combination oral products
Hallucinations and pimavanserin (NUPLAZID), a new kind of drug for psychosis • Hypotension with sacubitril-valsartan (ENTRESTO) for heart failure
Oral anticoagulants the nation’s top risk of acute injury from drugs • Millions at risk from withdrawal symptoms • FAERS: A key monitoring system suffering from continued neglect
Exploring the link with therapeutic drugs • Emotional problems linked to suvorexant (BELSOMRA) started with missed doses • Very different phosphodiesterase-4 (PDE4) drugs can cause psychiatric problems
Antidepressants, allergy drugs among 87 products with signals for insomnia • Liver failure and antiviral failure with hepatitis C direct-acting drugs • Harms of antipsychotic drugs reappraised
SGLT2 Inhibitors - a health gamble with a new class of drugs for diabetes • Oral anticoagulants linked to nearly 3,000 reported patient deaths, 16,000 hemorrhages • Overall opioid use drops, but oxycodone use grows